1 Followers
25 Following
chaitanyag11

chaitanyag11

Structural Heart Devices Market Research Report And Drivers 2019

Advanced products such as sutureless heart valve costs significantly higher than earlier available product.

Electric Dental Handpiece Market Opportunity Analysis, 2018-2026

Electric dental handpieces are devices by dentist to perform various procedures such as cavity preparation, crown preparation, decay removal, and endodontics. Electric dental handpieces utilizes electric motor, which is attached to a shaft with gears and these gears are attached with bur (part that performs actual cutting). Whereas, air driven dental handpiece run on compressed air that rotates the turbine, which rotates the bur. These electric handpieces have several advantages over air driven dental handpieces such as consistent speed and torque. Electric dental handpieces offer speed control (RPM from 100 to 2, 00000) and higher torque (greater cutting power), and produces less noise and less vibration, hence does not produce heat in the operating area. Other advantages include greater accessibility, more precise operation, and no malfunction of turbine as compared to air driven handpiece.

High prevalence of oral diseases is expected to drive growth of the electric dental handpiece market

Rising prevalence of oral diseases is expected to propel growth of the electric dental hand piece market. According to FDI World Dental Federation’s Oral Health Atlas, 2015, oral disease affected 3.9 billion people worldwide, with untreated tooth decay that impacts approximately 44% of world’s population. According to World Health Organization’s Oral Health factsheet, 2012, globally, 60–90% of schoolchildren and around 100% adults have tooth decay, often leading to pain and discomfort. Another factor for growth of the market is increasing aging population. For instance, according to WHO (World Health Organization) Oral Healthcare factsheet, 2012, globally, around 30% of people with age 65-75 years have no natural teeth and burden is expected to increase. Need for dentist across the globe is increasing, for instance according to WHO factsheet in 2017, 93% of its member nations has less than 1 dentist per 1000 population, electric dental hand piece market would prosper in near future as it is integral part of dentistry setup .

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1366

Advancements in technology and continuous improvement in dental hand pieces is another factor further expected to drive growth of the electric dental hand piece market. For instance, in August 2017, KaVO Dental GmbH launched electromatic series, which provides constant torque, controlled speed, low noise operation, and increased versatility, which would make transition from air driven handpiece to electric driven hand piece, easy for dentists. Other factors such as increasing demand for cosmetic dentistry would further aid in growth of the electric dental handpiece market, report by  The American Association of Oral and Maxillofacial Surgeons in 2016 has estimated that 69% of adults between the ages of 35 and 44 have lost at least one permanent tooth so they opts for cosmetic dentistry.

However, repairing of electric handpieces is expensive than air handpieces. Cost associated with replacement of parts of electric handpiece such as clutch assemblies, cartridge, and drive shaft is relatively expensive, which may hinder growth of the market. Also, problems related to reimbursement scenario with dental procedures may limit dentist visit by patients and is expected to negatively affect growth of the electric hand piece market.

North America and Europe are expected to exhibit high growth in the global electric dental hand piece market over the forecast period

Regions such as North America and Europe are expected to exhibit high growth in the global electric dental handpiece market, due to various factors such as increasing aging population, availability of high end dentistry instruments, and easy access of these devices to dentist. According to Centre for Disease Control and Prevention, 2012, 47.2% of adults over 30 years of age and older have some form of periodontal disease and 70.1% of adults aged 65 and above have periodontal disease in U.S. Europe is expected to be major market, owing to increasing expenditure of people in the region on oral health. For instance, according to report by Oral Health Platform of European Union, 2012, 27 European countries, together, accounted for US$ 97 billion expenditure, which is highest in world. North America market is in transition phase from air driven to electric driven hand pieces.

Key players in the global electric dental handpiece market are KaVo Dental GmbH, A-dec Inc., Dentsply Sirona Inc., Nakanishi Inc., Bien-Air Medical Technologies, DentalEZ Group, SciCan Ltd. Brasseler USA, W&H Group, Dentamerica Inc., Lares Research, J. Morita Corporation, and Being Foshan Medical Equipment Ltd.

Click To Read More On Electric Dental Handpiece Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Electric Dental Handpiece Market Opportunity Analysis, 2018-2026

Electric dental handpieces are devices by dentist to perform various procedures such as cavity preparation, crown preparation, decay removal, and endodontics. Electric dental handpieces utilizes electric motor, which is attached to a shaft with gears and these gears are attached with bur (part that performs actual cutting). Whereas, air driven dental handpiece run on compressed air that rotates the turbine, which rotates the bur. These electric handpieces have several advantages over air driven dental handpieces such as consistent speed and torque. Electric dental handpieces offer speed control (RPM from 100 to 2, 00000) and higher torque (greater cutting power), and produces less noise and less vibration, hence does not produce heat in the operating area. Other advantages include greater accessibility, more precise operation, and no malfunction of turbine as compared to air driven handpiece.

High prevalence of oral diseases is expected to drive growth of the electric dental handpiece market

Rising prevalence of oral diseases is expected to propel growth of the electric dental hand piece market. According to FDI World Dental Federation’s Oral Health Atlas, 2015, oral disease affected 3.9 billion people worldwide, with untreated tooth decay that impacts approximately 44% of world’s population. According to World Health Organization’s Oral Health factsheet, 2012, globally, 60–90% of schoolchildren and around 100% adults have tooth decay, often leading to pain and discomfort. Another factor for growth of the market is increasing aging population. For instance, according to WHO (World Health Organization) Oral Healthcare factsheet, 2012, globally, around 30% of people with age 65-75 years have no natural teeth and burden is expected to increase. Need for dentist across the globe is increasing, for instance according to WHO factsheet in 2017, 93% of its member nations has less than 1 dentist per 1000 population, electric dental hand piece market would prosper in near future as it is integral part of dentistry setup .

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1366

Advancements in technology and continuous improvement in dental hand pieces is another factor further expected to drive growth of the electric dental hand piece market. For instance, in August 2017, KaVO Dental GmbH launched electromatic series, which provides constant torque, controlled speed, low noise operation, and increased versatility, which would make transition from air driven handpiece to electric driven hand piece, easy for dentists. Other factors such as increasing demand for cosmetic dentistry would further aid in growth of the electric dental handpiece market, report by  The American Association of Oral and Maxillofacial Surgeons in 2016 has estimated that 69% of adults between the ages of 35 and 44 have lost at least one permanent tooth so they opts for cosmetic dentistry.

However, repairing of electric handpieces is expensive than air handpieces. Cost associated with replacement of parts of electric handpiece such as clutch assemblies, cartridge, and drive shaft is relatively expensive, which may hinder growth of the market. Also, problems related to reimbursement scenario with dental procedures may limit dentist visit by patients and is expected to negatively affect growth of the electric hand piece market.

North America and Europe are expected to exhibit high growth in the global electric dental hand piece market over the forecast period

Regions such as North America and Europe are expected to exhibit high growth in the global electric dental handpiece market, due to various factors such as increasing aging population, availability of high end dentistry instruments, and easy access of these devices to dentist. According to Centre for Disease Control and Prevention, 2012, 47.2% of adults over 30 years of age and older have some form of periodontal disease and 70.1% of adults aged 65 and above have periodontal disease in U.S. Europe is expected to be major market, owing to increasing expenditure of people in the region on oral health. For instance, according to report by Oral Health Platform of European Union, 2012, 27 European countries, together, accounted for US$ 97 billion expenditure, which is highest in world. North America market is in transition phase from air driven to electric driven hand pieces.

Key players in the global electric dental handpiece market are KaVo Dental GmbH, A-dec Inc., Dentsply Sirona Inc., Nakanishi Inc., Bien-Air Medical Technologies, DentalEZ Group, SciCan Ltd. Brasseler USA, W&H Group, Dentamerica Inc., Lares Research, J. Morita Corporation, and Being Foshan Medical Equipment Ltd.

Click To Read More On Electric Dental Handpiece Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Structural Heart Devices Market Research Report And Drivers 2019

Structural heart diseases refer to cardiac defects, which are congenital (by birth) in nature and also includes the abnormalities developed in valves and vessels of the heart caused by wear or tear due to some disease. Structural heart diseases is a non-coronary abnormality of heart, which does not affect the blood vessels in the heart. Common structural heart condition includes atrial septal defect, patent foramen oval, ventricular septal defect, paravalvular leak, arterial/venous fistulae, and congenital heart disease.

Structural Heart Devices Market Drivers

In 2017, Medtronic plc. received the U.S. Food and Drug Administration (FDA) approval for its new CoreValve Evolut PRO valve for the treatment of severe aortic stenosis in symptomatic patients who are at high or extreme risk for open heart surgery. Moreover, the company has launched CoreValve Evolut PRO valve in the U.S. market in the same year. In 2017, Medtronic plc. received CE Mark for its CoreValve Evolut R 34 mm valve and launched it in European market. CoreValve Evolut R 34 mm is the largest sized transcatheter aortic valve implantation (TAVI) system available in Europe. In 2015, Edwards Lifesciences Corporation, an U.S.-based company focused on heart valves and hemodynamic monitoring received U.S. Food and Drug Administration (FDA) approval for its Edwards SAPIEN 3 valve, a transcatheter aortic heart valve used for the treatment of high-risk patients suffering from severe, symptomatic aortic stenosis. Furthermore, companies operating in the area are looking to expand product portfolio through inorganic growth. For instance, in 2015, CryoLife, Inc., an U.S.-based medical device company acquired the U.S. based On-X Life Technologies Holdings, Inc., a privately held mechanical heart valve company. CryoLife, Inc. entered in mechanical valve market with On-X Life Technologies Holdings, Inc.’s products with this strategic acquisition.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1559

Structural Heart Devices Market Regional Analysis

North America is expected to hold a dominant position in global structural heart devices market, owing to continued research for the development of novel product and subsequent launches by major key players present in the region. For Instance, in 2017, Edwards Lifesciences Corporation, an U.S-based company is focusing on Launch of SAPIEN 3 Ultra and CENTERA Valves. SAPIEN 3 Ultra system is a next-generation platform with expandable Axela sheath technology and on-balloon delivery design. This novel product is expected to accelerate the make procedures with less chances of mistakes. Furthermore, Europe is expected to witness significant growth in structural heart devices market, owing to increasing prevalence of Valvular Heart Disease (VHD) in the region. According to a study published in British Medical Journal (BMJ) in 2017, incidence of VHD was 63.9 per 100 000 person-years, with aortic stenosis (AS; 47.2%), mitral regurgitation (MR; 24.2%) and aortic regurgitation (AR; 18.0%). The study analyzed nationwide hospital data between 2003 and 2010 to reach to this conclusion.

Structural Heart Devices Market Restraint

Advanced products such as sutureless heart valve costs significantly higher than earlier available product. For instance, the price of suture less heart valve, aortic manufactured by LivaNova, Plc. is more than US$ 9,000 whereas tissue heart valves manufactured by Medtronic Plc., and Abbott Laboratories costs around US$ 5,000 in the U.S. This almost double price of sutureless device has limited its adoption, which in turn is restraining growth of the market.

Structural Heart Devices Market Key Players

Key players in global structural heart devices market include Abbott Laboratories, Medtronic Plc., Edwards Lifesciences Corporation, Boston Scientific Corporation, CryoLife Inc., LivaNova Plc., Cook Group Incorporated, Endologix Inc., and W. L. Gore & Associates, Inc. Key players in the market are focused on strategic merger and acquisition in order to expand its structural heart device product portfolio. For instance, in 2017, Edwards Lifesciences Corporation, an U.S. based medical device manufacturer, acquired Harpoon Medical, Inc. in US$ 100 cash and additional US$150 million in milestone payments over 10 years. With this strategic acquisition Edwards Lifesciences Corporation has widen its offerings with mitral valve repair technology, which is designed to reduce the amount of time required for mitral valve surgery.

Click To Read More On Structural Heart Devices Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Tuberculosis Vaccine Market Analysis,Market Drivers And Restraints To 2026

It causes multisystem infection and eventually might lead to death of the infected person. Two types of TB that are commonly observed include latent TB in which the infected person do not show symptoms and active TB in which the infected person shows clinical symptoms of TB. Clinical symptoms and signs of TB include fever, night sweats, cough, weight loss, hemoptysis (coughing up blood-stained sputum), fatigue, chest pain, and shortness of breath. Depending upon the symptoms, TB may be classified as pulmonary TB, subcutaneous TB or military TB. Depending on the resistance it shows, TB may be multidrug resistant TB or extended drug resistant TB. Diagnosis of tuberculosis can be carried out using skin test, polymerase chain reaction test or interferon-gamma release assays. Initial treatment regime for active TB includes drugs such as ethambutol, pyrazinamide, isoniazid, and rifampicin. Although currently no TB vaccine is approved commercially, children are vaccinated with BCG vaccine as a part of precautionary measure. However, BCG vaccine has limited utility and variable efficacy in both adults and children. Many TB vaccines are under the stage of clinical development, which are expected to reach the market in the near future.

Tuberculosis Vaccine Market Dynamics

Tuberculosis account for the highest amount of death caused due to infectious disease across the globe. According to the World Health Organization (WHO) factsheet 2018 on TB, 10.4 million people fell ill with TB in 2016 and 1.7 million people with TB died in the same year. More than 95% of TB deaths occur in low- and middle-income economies. Deaths caused due to TB also includes death of 0.4 million people infected with HIV. Such high number of patients across the world confirms the enormity of disease and urgent requirements for vaccines worldwide. Therefore, the launch of tuberculosis vaccine would gain significant revenue and in turn, would propel the market growth. According to a global report on tuberculosis vaccine in 2018, TB costs around US$ 21 billion annually to global economy. Another important impetus to tuberculosis vaccine market would be current complex drug regime and resistance TB has created to this drug regime. TB patient has to take more than 2-3 drugs for prolonged time period of 6 months in order to suppress the infection.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1602 

Often this results in the poor patient compliance and eventually leads to drug resistance incidence which further deteriorate the TB. According to WHO, there were nearly 600,000 new cases with resistance to rifampicin antibiotic, which was the most effective first-line drug in 2017, of which around 490,000 had MDR-TB globally. If effective steps won’t be taken by 2050, MDR-TB alone could cost the world US$ 16.7 trillion as per global report on tuberculosis vaccine 2018. Drug toxicity due to high daily dose and prolonged treatment is another concern with current TB drugs. Although the cost of TB drug is not much of concern in developing economies due to government support and free medication, it is a matter of concern in developed countries such as the U.S. and Europe. Increased recognition of TB’s fatality by intergovernmental organization and national government would prosper funding for TB vaccine research. Increased research and development activities for development of vaccine against TB by companies and intergovernmental organizations is expected to boost growth of tuberculosis vaccine market. For instance, Aeras is an NGO, which supports TB vaccine development and has helped develop 9 TB vaccine candidates and conducted over 35 Phase 1-2b clinical trials.

Tuberculosis Vaccine Market – Regional Insights

TB is most prevalent in middle and low income economies in Asia Pacific and Africa and therefore, these regions would represent greatest opportunity for the potential TB vaccine. According to the World Health Organization factsheet 2018 on TB, countries such as India, China, Indonesia, Philippines, Pakistan, Nigeria, and South Africa account for around 64% of the total TB deaths. Another risk factor for these regions is the high number of HIV positive population living in this region. Around 40% of deaths among HIV-positive people were due to TB in 2016 as per WHO. Tuberculosis vaccine could prove most beneficial for these regions and in turn, would drive growth of tuberculosis vaccine market. Government initiatives and international support to curb TB incidence would speed up the vaccine development and also would support access for such vaccines. India, which accounts for half a million global TB deaths has launched National Strategic Plan (NSP) for TB Elimination 2017-2025 to combat TB. India also formed India TB Research Consortium to boost TB vaccine and medication research. Developed regions such as North America accounts for significant number of TB patients. According to the Centre for Disease Control, a total of 9,093 TB cases were reported in the U.S. in 2017. MDR-TB and XDR-TB accounted for approximately US$ 160,000 and US$ 513,000 respectively for treatment of each patient. Effective vaccine against TB would gain significant traction in countries such as the U.S.

Tuberculosis Vaccine Market – Competitive Landscape

Many companies and research institutes are taking efforts to develop tuberculosis vaccine to combat TB. There are fourteen TB vaccines under clinical trials, out of which one investigational candidate named Vaccae from China is in phase three whereas three are in late phase 2. Most of the researches are carried out in academic and research places, which eventually would be transferred to commercial companies for effective distribution and access. Companies are also improving current BCG vaccines, in order to target TB by bringing recombinant vaccine product.

Some of the key players in the tuberculosis vaccine market include GlaxoSmithKline, Sanofi Pasture, Longcom Enterprise Ltd, Biofabri, Valneva plc, and Archivel Farma S.L.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1602

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Small Molecule Prefilled Syringes Market 2019 : Prime Challenges, Competitive Scenario

The global small molecule prefilled syringes market was valued at US$ 13,749.4 million in 2016 and is expected to witness a robust CAGR of 4.6% over the forecast period (2017–2025).

Manufacturers are focusing on capitalizing on patent losses to launch generic versions in the market. For instance, in 2017, Mylan N.V. launched generic alternative to Copaxone 40 mg/ml for multiple sclerosis patients in the U.S. Moreover, Mylan N.V. launched Brabio, first generic alternative to Copaxone 40 mg/ml, for multiple sclerosis patients in the U.K., in January 2018. Teva Pharmaceuticals enhanced presence in Multiple Sclerosis segment through the introduction of three-times-a-week Copaxone 40 mg/mL product in the U.S in 2014. In 2015, Teva Pharmaceuticals launched Generic Lovenox in the U.S. market. In 2016, Fresenius Kabi launched Ketorolac injection in its ready-to-administer prefilled glass syringe. Sandoz announced the U.S. Food & Drug Administration approval and launch of Glatopa (Glatiramer acetate) 40 mg/mL, in February 2018.

Key players in the market are focusing on collaborations, acquisitions, and partnerships, in order to enhance their market share. For instance, in 2013, Unilife Corporation entered into a long term supply contract with Sanofi S.A. The objective was to use Unilife’s Unifill Finesse platform of prefilled syringes with Sanofi S.A.’s Enoxaparin Sodium sold under brand names, Lovenox and Clexane. Pfizer, Inc. acquired Hospira, Inc. in the year 2015. Hospira, Inc. was a leading provider of injectable drugs and infusion technologies and this is expected to aid the company in increasing its market share. In 2016, Fresenius Kabi USA acquired BD Rx business from Becton, Dickinson, and Company. The business included pharmaceutical manufacturing plant and the BD Simplist line of seven drugs in ready-to-administer prefilled glass syringes.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1629

Key Takeaways of the Small Molecule Prefilled Syringes Market:

The global small molecule prefilled syringes market is expected to exhibit a CAGR of 6% over the forecast period (2017–2025), owing to increasing product launches by manufacturers such as Mylan N.V., and Fresenius Kabi, AG in this prefilled syringes

Availability of small molecule therapies in neurology segment is very low and therefore, the segment has high growth potential

Major drugs in the neurology drugs segment such as Copaxone (manufactured by Teva Pharmaceutical Industries Ltd.) are expected to face competition from generics

Major players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson, and Company, and Fresenius Kabi AG

However, factors such as complex manufacturing process, high costs, and requirement of high quality of these products (responsible for high costs) are expected to hinder growth of the market over the forecast period.

Some major players operating in the small molecule prefilled syringes market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, and Fresenius Kabi AG.

Click To Reading More On Small Molecule Prefilled Syringes Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Oxygen Conservation Devices Market-By End User Hospitals, Clinics, Nursing Home, Home Care

Oxygen conserving device (OCD) is a pressure reducing device designed to control the flow of oxygen from the oxygen source to the patient.

Phenylketonuria Treatment Market : Repository of Analysis and Information for Every Fact of the Market

Phenylketonuria (PKU) is a rare genetic disorder caused due to increased level of phenylalanine in the blood. The excess amount of phenylalanine can cause intellectual disability and other serious health problems. The most severe condition of this disorder is termed as classic PKU and symptoms related to it are seizures, tremors, or trembling and shaking, stunted growth, hyperactivity, skin conditions such as eczema, and musty odor of their breath, skin, or urine. PKU can be managed by maintaining phenylalanine free diet. KUVAN (sapropterin dihydrochloride) is a U.S. Food and Drug Administration approved drug which is majorly used in the treatment of Phenylketonuria.

Phenylketonuria Treatment Market Drivers

Frequent research for development of novel drugs for the treatment of phenylketonuria is expected to drive growth of global phenylketonuria treatment market in the near future. For instance, in 2017, BioMarin Pharmaceutical Inc. submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its new Pegvaliase, indicated for the treatment of patients with Phenylketonuria (PKU). In 2018, European Medicines Agency (EMA) accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of adults with phenylketonuria (PKU) who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l). In 2017, Synlogic, Inc. received Orphan Drug Designation for its SYNB1618 from U.S. Food and Drug Administration. SYNB1618, an orally administered synthetic biotic medicine indicated for the treatment of PKU. Furthermore, increasing acquisitions and collaborations between key players is also expected to create a lucrative environment for growth of global phenylketonuria treatment market. For instance, in 2015, BioMarin Pharmaceutical Inc. acquired all global rights of Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono (Merck). Kuvan is an oral therapy indicated for the treatment of hyperphenylalaninemia (HPA) due to phenylketonuria (PKU). Pegvaliase (PEGylated recombinant phenylalanine ammonia lyase) is an investigational enzyme substitution therapy for the treatment of phenylketonuria (PKU). In 2016, Dimension Therapeutics, Inc. entered into a gene therapy research collaboration with the University of Pennsylvania for research and development of novel treatment for phenylketonuria.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1648

Phenylketonuria Treatment Market Regional Analysis

North America is expected to hold a dominant position in global phenylketonuria treatment market, owing to initiatives taken by governments for the diagnosis and treatment of phenylketonuria in the region. For instance, in 2017, The National PKU Alliance and Baby Genes launched a program to allow easy access to genetic testing for people with phenylketonuria, and their families. The program aims to help in diagnosis and assist the people for treatment of phenylketonuria. Furthermore, launches of novel products by U.S.-based key players is also expected to drive growth of North America phenylketonuria treatment market. For instance, in 2017, Vitaflo USA, LLC launched its new PKU Sphere, a low phenylalanine medical food used in dietary management of Phenylketonuria (PKU). Europe is also expected to exhibit significant growth in the near future, owing to increasing approval of new drugs in the region. For instance in 2015, Merck Group, a Germany-based company, received EU-approval to extend the use of Kuvan in children below four years of age suffering from Phenylketonuria.

Phenylketonuria Treatment Market Restraint

According to data published by The ZB Foundation in 2017, Phenylketonuria is a rare inherited disease that affects only about 1 in 10,000 to 15,000 newborn children. The lack of awareness about the rare disease is a major factor, which is expected to restrain growth of the market in the near future.

Phenylketonuria Treatment Market Key Players

Key players operating in global phenylketonuria treatment market include BioMarin Pharmaceutical Inc., Dimension Therapeutics, Inc., American Gene Technologies International Inc., Synthetic Biologics, Inc., Codexis, Inc., SOM Innovation Biotech SL, Daiichi Sankyo Company, Limited, and Erytech Pharma SA. Key Players in global phenylketonuria treatment market are focusing on strategic collaborations for the development of novel therapies for the treatment of phenylketonuria. For instance, in January 2018, Retrophin, Inc. and Censa Pharmaceuticals collaborated for the development and evaluation of CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001, is an orally bioavailable proprietary form of sepiapterin, serves as a natural precursor of tetrahydrobiopterin (BH4) that is converted by an endogenous enzymatic pathway to BH4.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1648

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Oxygen Conservation Devices Market : Expert Forecasts and Analysis

Oxygen conserving device (OCD) is a pressure reducing device designed to control the flow of oxygen from the oxygen source to the patient. Oxygen conservation devices are used for the patients with severe lung diseases such as chronic obstructive pulmonary disease, diffuse interstitial lung disease, cystic fibrosis or hypoxia related symptoms, which requires long-term oxygen therapy to maintain a normal lifestyle. According to the global asthma report by Global Asthma Network, 2014, asthma has affected around 334 million people so far and prevalence is rising continuously. This suggests the occurrence of severe asthma cases in low and middle-income economies such as India and China. This device offers comfort and increased mobility to the patients. The main aim of manufacturers is to develop efficient, portable, and less intrusive oxygen conservation devices.

Oxygen conservation devices are mainly of two types – pneumatic oxygen conservation devices and electronic oxygen conservation devices. Pneumatic oxygen conservation devices use high pressure of oxygen gas and do not require any external power source such as battery, whereas electronic oxygen conservation devices are battery supported. For instance, Invacare’s Invacare Pneumatic Oxygen Conserver is a pneumatic oxygen conservation device, which has an on and off selector knob coupled with liter flow and continuous flow mode. CHAD therapeutics’ Evolution Electronic Oxygen Conserver requires two AA batteries for its functioning. The Invacare has consistent volume delivery whereas Evolution is featured with pulse ranging from 14 to 40 breathes per minute. The key driver propelling the oxygen conservation devices market is increasing population of patients with chronic lung disorder. Moreover, favorable rental policies and reimbursement policies are driving the present oxygen conservation devices market. However, as a medical device, oxygen conservation device market is expected to be restrained by the stringent regulatory policies employed by the regulatory bodies to monitor the efficacy to the device.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1659

Oxygen Conservation Devices Market Drivers

Large pool of chronic obstructive pulmonary diseases (COPD) and other lung diseases are expected to fuel growth of oxygen conservation devices market. For instance, in 2014, Centers for Disease Control and Prevention (CDC) reported around 1,417,101 deaths globally due to chronic respiratory diseases. Moreover, high prevalence of smoking tobacco is expected to add to the pool of lung diseases. According to Inogen Inc., there were 2.5 to 3 million patients in the U.S. and more than 4.5 million patients worldwide who used oxygen therapy in 2015. Furthermore, the number of oxygen therapy patients in the U.S. increased from around 7% to 10% between 2015 and 2021.

Moreover, as these devices are life supporting devices, oxygen conservation devices are supported by the regulatory policies for oxygen therapy by providing the facility at minimal cost. These oxygen conservation devices are covered under the Medicare Program, according to which around 20% of the cost is only paid by the patient. Moreover, awareness about COPD is spread through various governmental and non-governmental initiatives. For instance, Global Initiative for Chronic Obstructive Lung Disease (GOLD) in collaboration with health care professionals and COPD patients initiated World COPD Day, which began from 2002. For instance, in 2014, American Lung Association launched a campaign called as LUNG FORCE, which focused on research and better treatment option for lung diseases.

Oxygen Conservation Devices Market - Regional Analysis

On the basis of region, the global oxygen conservation devices market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the oxygen conservation devices market, owing to highly supportive reimbursement policies and high patient population. For instance, Medicare and Medicaid policies of the U.S. offers reimbursement on the prescribed oxygen therapy. However, Asia Pacific is expected to witness significant growth, owing to increasing incidence of asthma and increasing government initiatives to create awareness about the presence of devices such as oxygen conservation device. According to the article in journal Asia Pacific Allergy, 2014, asthma is a major chronic disease in Asia and prevalence of childhood asthma is observed to be continuously increasing over the last decade (2003-2013)

Oxygen Conservation Devices Market – Competitive Landscape

Some of the key players operating in the global oxygen conservation devices market include Medline Industries, Inc., Invacare Corporation, Responsive Respiratory Inc., Drive Medical, DeVilbiss Healthcare Ltd., Precision Medical, Inc., Hersill, S.L., Inogen, Inc., and Essex Industries, Inc.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1659

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

Surgical Navigation System Market expected to witness a CAGR of 6.9%

The global surgical navigation system market was valued at US$ 673.1 million in 2017 and is expected to witness a CAGR of 6.9% over the forecast period (2018–2026).

Surgical navigation is a method to guide surgery with the help of medical images as the guidance map. Surgical navigation system aims at maximization of the effect of the treatment while minimizing the damage to critical structure. Major area of application for surgical navigation system included minimally invasive and non-invasive surgical procedure in field of neurology, ENT, cardiology, odontology and orthopedics. Surgical navigation system is designed to provide improved intraoperative feedback and alignment validation to surgeons during surgical procedures. For example, neuronavigation system displays human anatomical structures coupled with tracked instrument’s virtual axis, used to optimize craniotomy by locating underlying tumor border. Increasing incidences disorder related to ENT, spine and neurons will propel the market growth. For instance, according to Centers for Disease Control and Prevention (CDC), in 2017, in US 29.4 million adults are diagnosed with Sinusitis, inflammatory disease of nose, comprises 12.1% of the population.

Market players are adopting various inorganic growth strategies for maintaining leading position in the market. For instance, in 2016, Fiago GmbH, a manufacturer of clinical navigation systems, together with Beta Klinik GmbH, an international private clinic, opened conference center for navigation neurosurgery in Bonn. Fiagon.Tracey technology assists surgeon by visualizing complex structures of brain and spine. Moreover, commercialization and investment by company plays important role in growth of market. For instance, in February 2018, 7D Surgical, developer of optical technologies and machine vision-based registration algorithm for surgical workflow, company provided funding for the commercial launch of it FDA approved Machine-vision Image Guided Surgery (MvIGS) system used for spinal and cranial navigation.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1690

Increasing demand for minimally invasive surgeries is expected to fuel growth of the surgical navigation system market in the forecast period

Minimally invasive surgical procedures are conducted by computer-assisting surgery aided by surgical navigation system. The robotic-assisted orthopedic surgical solution are cost-effective, time efficient and user-friendly. Advancement in technology and increasing surgical products propel the adoption of minimally invasive and non-invasive surgeries. However, minimally invasive or non-invasive surgical procedure is the more opted over open or traditional surgeries in the developed countries like US, trend is expected to spread in other regions in forecast period subjecting to the growth of surgical navigation market.

Additionally, increasing adoption of robot assisted surgery will fuel the market growth. For instance, in 2017, Hartford HealthCare (HHC), pioneered a new and advanced technology at The Hospital of Central Connecticut, became first hospital in New England to use Globus ExcelsiusGPS, a sophisticated surgical guidance system for spinal procedures by Globus Medical. However, the product recalls is expected to hamper the growth of the market. For instance, in 2017, Brainlab’s Cranial IGS System, a navigation system, faced product recall for 1021 units from US due to potential inaccuracies in the display by the navigation system compared to the patient anatomy.

Global surgical navigation system market is occupied by few of the well-established market players such as Medtronic PLC, Stryker Corporation, Brainlab AG, B. Braun Melsungen AG, Scopis GmbH, Fiagon GmbH, Zimmer Biomet Holdings, Inc., Amplitude Surgical and Siemens Healthcare Corporation.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1690

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Pain Management Drugs Market - Global Forecast to 2026

The global pain management drugs market was valued at US$ 63,212.3 Mn in 2017 and is expected to witness a robust CAGR of 3.9% over the forecast period (2018 – 2026).

Pain Management Drugs Market - Global Forecast to 2026

The global pain management drugs market was valued at US$ 63,212.3 Mn in 2017 and is expected to witness a robust CAGR of 3.9% over the forecast period (2018 – 2026).

Pain management medications are specific drug classes, which have pharmacological actions on pain receptors and work against the pain symptoms. These medications include opioids, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants, muscle relaxants, and others. These medications can be used for pain management of conditions, as indicated on label and some medications have off-label uses. For instance, anticonvulsants and antidepressants were originally used for the management of epilepsy and depression respectively. However, these medications have shown activity against pain indications and are prescribed for pain management as off-label indication. Moreover, opioids are majorly prescribed for the management of acute as well as chronic pain. This has also resulted in self-medication by patients, resulting in misuse or overdose of opioid containing drug products. Moreover, majority of the drugs have lost patent protection over the years and generic versions of the same are widely available in the market. Commercially available pain management drugs include Fentanyl, Hydromorphone, Oxycodone, Aspirin, Diazepam, and others.

Lack of alternative treatment therapies are projected to drive growth of pain management drugs market over the forecast period

In 2015, Depomed, Inc. acquired the U.S. rights to NUCYNTA (tapentadol), NUCYNTA ER (tapentadol) extended release tablets, and NUCYNTA (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. Tapentadol is available in tablet, solution, and extended release forms. Furthermore, the tablet and solution forms of NUCYNTA has three patents, out of which one expired in June 2017 and other two will expire in June 2025 and August 2029, respectively. Moreover, patent expiry of pain management drugs such as Oxycontin, Opana, Celebrex (2013 - 2014), and others are providing opportunity to market players for introducing new products in the pain management drugs market.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1697

According to the American Academy of Pain Medicine, in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from chronic pain. According to a study published in the British Medical Journal in 2016, nearly one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according to the NIH estimates published in 2015 by the American Pain Society, around 50 million people in the U.S. suffered from chronic pain. Moreover, rising prevalence of pain and increasing prevalence of diseases such as cancer and others are driving growth of the pain management drugs market. For instance, according to the National Cancer Institute, in 2018, around 1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are expected to die from the disease.

However, side effects associated with the pain management drugs and addiction issues with the opioid medications are expected to hinder growth of the pain management drugs market over the forecast period.

Some major players operating in the pain management drugs market include Pfizer, Inc., Sanofi S.A., Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Abbott Laboratories, Purdue Pharma L.P., GlaxoSmithKline Plc, Johnson & Johnson, and F. Hoffmann La Roche Ltd.

Get HOLISTIC Request Sample Copy Of This Business Report:

https://www.coherentmarketinsights.com/insight/request-sample/1697

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Pneumonia Testing Market Size, Status and Forecast 2018-2026

North America accounted for the largest share in the pneumonia testing market, followed by Europe market in 2016.

Pneumonia Testing Market Size, Status and Forecast 2018-2026

The blood tests are used to confirm an infection and to try to identify the type of organism causing the infection, but however precise identification is not always possible through the blood tests. Further, the chest X-ray also helps the doctor to diagnose pneumonia and determine the extent and location of the infection. The chest X-ray can also detect the kind of germ is causing pneumonia. The pulse oximetry test is performed to measure the oxygen level in the blood, as Pneumonia can prevents lungs from moving enough oxygen into the bloodstream. Besides all these test the sputum test is used to analyses or pinpoint the cause of the infection with the sample of fluid from lungs, which is taken after deep cough.

Furthermore, if the pneumonia isn’t clearing as quickly as expected the doctors recommend a chest CT scan to obtain a more detailed image of the lungs. Moreover, if the patients shows serious symptoms or health conditions pleural fluid culture test is carried out where a fluid sample is taken by putting a needle between the ribs from the pleural area to analyze the type of infection.

Pneumonia Testing Market Dynamics

The recent advancements in pneumonia testing systems, such as the development of enhanced nucleic acid detection tests and advancement in POC tests is the major factor that contributes toward the growth of the pneumonia testing market size. As POC tests offers multiple benefits offered such as, ease of use, and rapid results. For instance, The urinary antigen is an extremely-effective rapid test that allows targeted therapy foe legionnaire at the point-of-care itself.

Further, increasing adoption of molecular diagnostic test in the developing economy is anticipated to provide lucrative opportunities to the pneumonia testing market. Due to increased application of biomarkers in molecular diagnostic, due to advantages of biomarkers such as aiding in early detection of specific diseases, supports the molecular diagnostics test for pneumonia testing market.

Initially, in the traditional method, cultures are used to detect pneumonia causative organisms. This is a time-consuming process with a higher error rate when compared to rapid diagnostics. In a few cases such as legionella, culture identification is not readily available and this increases the mortality rate of pneumonia cases caused by it.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1742

Pneumonia Testing Market - Regional Insights

North America accounted for the largest share in the pneumonia testing market, followed by Europe market in 2016. This is attributed to growing popularity for POC tests within the healthcare sector. Further, the ongoing research and development activities are also on rise for the development of more advanced PCR-based technologies, which could be used for faster results.

Further, pneumonia testing market in accounts second largest share in Europe region, primarily because of their robust, well-developed healthcare infrastructure and a greater awareness of a geriatric population likely to develop such health issues.

Furthermore, several pharmaceutical and biotechnological companies are focusing on expanding in Asia Pacific region, to maximize on their R&D efforts as the Asia Pacific region provides better access to patients for clinical trials, with lower cost operational efficiencies. Increasing government investment in research and development is also expected to foster growth of Pneumonia Testing in Asia Pacific region.

Pneumonia Testing Market - Competitive Analysis

Major players are focused on collaborations and mergers, to enter the pneumonia testing market. For instance, in April 2017, Abbott acquired Alere, which dominated POC testing for pneumonia testing market with its BinaxNOW Streptococcus pneumoniae antigen card for bacterial pneumonia and BinaxNOW RSV Card for viral pneumonia.

Key players operating in the market are Thermo Fisher Scientific Inc., Abbott Laboratories, F-Hoffmann la Roche Ltd., Hologic Inc., bioMerieux, Becton, Dickenson and Company, Bio-Rad Laboratories Inc., Meridian Biosciences, Quest Diagnostics, and Quidel.

Click To Reading More On Pneumonia Testing Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Hunter Syndrome Treatment Market Report Released Forecasting Movement in the Industry

Hunter syndrome also called as Mucopolysaccaridosis type II (MPS II), is the disorder affecting several parts of the body. Hunter syndrome is inherited genetic disorder caused by a malfunctioning or missing enzyme.

Hunter Syndrome Treatment Market Report Released Forecasting Movement in the Industry

Hunter syndrome also called as Mucopolysaccaridosis type II (MPS II), is the disorder affecting several parts of the body. Hunter syndrome is inherited genetic disorder caused by a malfunctioning or missing enzyme. At birth hunter syndrome individuals do not display any features of the disorder, amid ages 2 and 4, changes starts to show as large round cheeks, an enlarged tongue, full lips, and a broad nose. As the disorder advance’s, individuals need more medical assistance. According to the National Institute of Health 2018 report, Frequency of MPS II is 1 in 100,000 to 1 in 160,000 in males. Hunter syndrome is of two type, severe and mild. These both affect many different tissues and organs. Individuals suffering from severe type condition experience a decline in rapid intellectual function and disease progression. Individuals with the severe case begin to lose basic functional skills between at the ages of 6 and 8. The normal life expectancy of these people is 10 to 20 years. Individuals with mild type also have a shortened lifespan, they live into adulthood and their intelligence is not affected, major causes of death in these individuals is airway obstruction and heart disease. Several diagnostic tests are performed to diagnose hunter syndrome, which includes iduronate-2-sulfatase (I2S) enzyme activity test and a genetic testing. The urine test for GAGs is the most frequently used laboratory screening test for an MPS disorder. Advantages offered by this diagnosis test such as quick results and rapid diagnosis is driving growth of the hunter syndrome treatment market globally.

Hunter Syndrome Treatment Market – Dynamics

As Hunter syndrome has no permanent cure, the treatment mainly focuses on management of indications, signs, and difficulties associated with the disease advancement. Increasing number of population suffering from hunter syndrome has boosted the market growth for Hunter syndrome treatments.  For instance, in 2014, around 970 patients were enrolled in Hunter Outcome Survey (HOC) which increased to 1195 patients in 2017. Moreover, high burden of rare diseases, tax warier, fee reductions and grants, success for the drugs in pipeline with faster market access, financial incentives for orphan drug development to recover R&D costs, favorable regulations for orphan products development are some of the factors expected to fuel market growth over the forecast period. Rising attention of major biopharmaceutical companies on research and development of drugs for treatment of rare diseases is expected to boost demand for mucopolysaccharidosis treatment drugs. Moreover, the number of treatment options currently in pipeline is expected to boost the growth of market during the forecast period.

However, various issues limiting the market growth are heterogeneity of the disease, high cost of treatment, and lack of awareness are some the factors are restraining the growth of the market.

Download the PDF brochure:

https://www.coherentmarketinsights.com/insight/request-pdf/1749

Hunter Syndrome Treatment Market – Regional Insights

On the basis of region, the global blood stream infection testing market is segmented into North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America accounted for the largest market share in the global hunter syndrome treatment market due to favorable funding for research and development, better medical facilities, regulations for orphan products development, and rising awareness among the people regarding disrobers and disease. For instance, in 2017, Research funded by the National Institute of Neurological Disorders and Stroke (NINDS) has shown that viral-delivered gene therapy can stop the buildup materials stored in the brain cells and improve memory and learning. In the recent years, health insurance coverage and various reimbursement policies for such costly drugs also influencing pharmaceutical companies to invest in drug development. Moreover, Introduction of particular orphan drug regulations has allowed and increased research and development of various therapies for treatment of several such rare diseases. Developing healthcare infrastructure in Asia Pacific region is providing an opportunity for biopharmaceutical companies to penetrate in this region, which is fueling growth of the market.

Hunter Syndrome Treatment Market – Competitive Landscape

Key players operating in the global hunter syndrome treatment market include ArmaGen, Inc., BioMarin Pharmaceutical, Inc., Genzyme, Sangamo Therapeutics, a Sanofi Company, and others. Key players are engaged in developing new technologies and collaborations in order to retain dominant position in the market. For instance, in 2014, Shire Plc announced collaboration with ArmaGen to develop AGT-182 drug for treatment of hunter syndrome.

Click To Reading More On Hunter Syndrome Treatment Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.